Ascorbate-dependent decrease of the mucosal immune inflammatory response to gliadin in coeliac disease patients by Bernardo, David et al.
TITTLE:  
Ascorbate-dependent decrease of the mucosal immune inflammatory response 
to gliadin in celiac disease patients 
 
SHORT TITTLE:   
Ascorbate inhibition to gliadin. 
 
AUTHORS:  
David Bernardo1, Beatriz Martínez-Abad1, Sara Vallejo-Diez1, Enrique 
Montalvillo1, Verónica Benito1, Luis Fernández-Salazar2, Alfredo Blanco-
Quirós1, Jose A. Garrote1,3, Eduardo Arranz1. 
 
AFFILIATIONS: 
1. Mucosal Immunology Lab, Department of Paediatrics & Immunology, and 
IBGM, Universidad de Valladolid-CSIC, Spain. 
2. Gastroenterology Service, Hospital Clínico Universitario, Valladolid, 
Spain 
3. Research Unit, Hospital Clínico Universitario, Valladolid, Spain 
 
CORRESPONDING AUTHOR: 
Eduardo Arranz 
Mucosal Immunology Lab, Dept of Paediatrics & Immunology, and IBGM, 
Universidad de Valladolid-CSIC, Spain. C/ Ramón y Cajal, 7. 47005. Valladolid, 
Spain. 
Tel: +34 983 18 48 43 
First Page
E-mail: earranz@med.uva.es 
 
AKNOWLEDGEMENTS: 
Spanish Ministry of Education (FPU, AP2002-2696), Junta de Castilla y León 
(FPI fellowship), Universidad de Valladolid (FPI fellowship), Instituto de Salud 
Carlos III, Spanish Ministry of Health (PI 070244 and CES08/016), Fundación 
IECSCYL, Junta de Castilla y León (SAN-GRS232/B/08) and Phadia Spain. We 
also thank to Ms. Alicia Ortega for her technical help. 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
TITTLE:  
Ascorbate-dependent blockage of the immune response to gliadin in coeliac 
patients.  
 
SHORT TITTLE:   
Ascorbate inhibition to gliadin 
 
AUTHORS:  
D. Bernardo1, B. Martinez-Abad1, S. Vallejo-Díez1, E. Montalvillo1, B. Anta1, L. 
Fernández-Salazar2, A. Blanco-Quirós1, J.A. Garrote1,3, E. Arranz1. 
 
AFFILIATIONS: 
1. Mucosal Immunology Lab, Department of Paediatrics & Immunology. 
Universidad de Valladolid, IBGM-CSIC, Spain. 
2. Gastroenterology Service, Hospital Clínico Universitario, Valladolid, 
Spain 
3. Research Unit, Hospital Clínico Universitario, Valladolid, Spain 
 
KEYWORDS 
Coeliac Disease, IL-15, ascorbate, inhibition, therapy 
 
CORRESPONDING AUTHOR: 
E. Arranz 
Mucosal Immunology Lab, Dept of Paediatrics & Immunology, Universidad de 
Valladolid-IBGM, Spain. C/ Ramón y Cajal, 7. 47005. Valladolid, Spain. 
Tphn: +34 983 18 48 43 
E-mail: earranz@med.uva.es 
*Manuscript
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
ABSTRACT 
BACKGROUND: Innate immunity, through the IL-15/NF-κB axis, has an 
important role in Coeliac Disease (CD) that may represent a molecular target for 
its immunomodulation.  Therefore, we studied if ascorbate supplementation (a 
blocker of the NF-κB activation) to gliadin challenges could inhibit the immune 
response to gliadin.  
METHODS: Duodenal biopsy explants from treated CD patients were gliadin 
challenged in vitro (100/ml) with and without 20mM ascorbate. One extra 
explant basal cultured constituted and internal control. Nitritites (3 hours) and 
IFN-γ, TNF-α, IFN-, IL-17, IL-13 and IL-6 (24 hours) secretion were measured 
on the supernantants. IL-15 was assayed by Western-blot on the whole protein 
duodenal explant. 
RESULTS: The addition of ascorbate to gliadin-challenges blocked the 
secretion of nitrites (p=0.013), IFN (p=0.0207), TNF (p=0.0099), IFN 
(p=0.0375) and IL-6  (p=0.0036) compared to non-ascorbate supplemented 
gliadin-challenged supernatants. Also, cytokine secretion was downregulated by 
ascorbate even to lower values than those observed in basal cultures (IFN: 
p=0.0312; TNF: p=0.0312; IFN: p=0.0312; and IL-6: p=0.0078). After gliadin-
challenge, gliadin induced IL-15 production in treated-CD patients while the 
addition of ascorbate to culture medium completely inhibited IL-15 production. 
Moreover, the IL-15 inhibition by ascorbate took place even in the only treated 
CD-patient who had basal IL-15 production. 
CONCLUSIONS:  
Ascorbate blocks the immune response to gluten in a biopsy culture model, so It 
might be revealed as a possible future alternative therapy in CD. 
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INTRODUCTION 
Coeliac Disease (CD) is a gut hypersensitivity to wheat gluten and similar 
proteins of cereals affecting genetically predisposed individuals (HLA-
DQ2/DQ8). The current treatment is a life-long strict gluten-free diet (GFD) (1, 
2).  
The most accepted model of the CD immunopathogenesis is the two-signal 
model, which establishes that gliadin has a dual effect on the CD duodenum, 
first triggering the development of an innate immune response which then 
facilitates the activation of the adaptive immune response (3) controlled by 
gluten-reactive T cells with a TH1 cytokine profile characterized by interferon γ 
(IFNγ) (4). Innate immunity, and specifically IL-15 (5, 6), play a key role in the 
development of CD through a DQ2-independent mechanism (7). The induction 
of IL-15 in the CD duodenum is considered to be involved in the initial stages 
leading to epithelial stress, increase tight-junction permeability, enterocyte 
apoptosis and dendritic cell (DC) activation (5, 6, 8, 9, 10, 11, 12), facilitating 
the development of the secondary adaptive response (3). The innate DQ2-
independent IL-15 triggering effect of gluten is elicited through a Nuclear Factor 
(NF)-κB mechanism (13) with a positive feedback due to IL-15, also a potent 
NF-κB activator (14). Moreover, DCs which are important players in the 
connexion between the innate and the subsequent adaptive immune response 
(15) require NF-kB for DC development, survival, function and cytokine 
production (16, 17, 18). Therefore, the IL-15/NF-κB axis is revealed to have an 
important role in the CD and may therefore represent a molecular target for the 
modulation of the CD immunopathogenesis (19).  
NFkB is a heterogeneous collection of dimeric proteins composed of various 
combinations of members of the Rel family proteins whose classical pathway is 
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required for activation of innate immune responses. The NF-kB members are 
subject to a complex regulatory mechanism (20, 21) including the inhibitor 
proteins I-κB, bound to NF-κB subunits which became active after dissociation. 
This dissociation takes place when NF-κB inducers phosphorylate I-κB, which 
targets the inhibitor protein for degradation by the 26S proteaseome (22) 
releasing NF-κB dimers to translocate and elicit its function. The I-κB 
phosphorylation is derived of two I-κB kinases (IKKs), as part of a larger 
multriprotein complex (23).  
It has been recently proposed that vitamin C (ascorbate), may be able to inhibit 
IKK activation, which therefore inhibits I-κB phosphorylation and as a result NF-
κB cannot translocate and bind to its DNA targets (24). Ascorbate has been 
shown to elicit its inhibitory properties at concentrations of 20mM, which occur 
intracelluarly in vivo. Moreover, at these concentrations ascorbate is not toxic to 
cells, neither inhibits other inducible factors, like STAT1, nor have any effect on 
DNA binding of NF-κB, because of the properties of its mechanism (24).  
Given the central role of the NF-κB pathway in CD immunopathogenesis, 
ascorbate is revealed as an early immunity blocker which might be used as an 
alternative and/or complementary therapy to GFD on CD patients. To address 
this question we have performed culture of biopsies from CD patients and in 
vitro gliadin challenge with and whithout supplementation of ascorbate. The 
obtained data confirmed the blocking effect of ascorbate since its addition 
inhibited the gliadin-induced IL-15 triggering in CD biopsy explants. 
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MATERIALS AND METHODS 
Study Subjects 
We studied 8 CD patients treated on a GFD (mean age 41.7 years (yr), range 
23-68 yr, 25.0% males) and 3 non-CD healthy controls (mean age 63.6 yr, 
range 61-68, 0.0% males). The diagnosis of CD was based on compatible 
symptoms, positive serology (IgA antiendomysial or antitransglutaminase 
antibodies), genetics (HLA-DQ2/8), and mucosal changes in the duodenal 
biopsy. At the time of sample collection, CD patients had mucosal recovery 
(Marsh 0-1) and negative serology for at least one year. Healthy controls were 
referred to the Gastroenterology Clinics due to other intestinal diseases which 
were later ruled out, and no mucosal alterations were found in the duodenum. 
All patients attended to the Adult Gastroenterology Clinics from the “Hospital 
Clínico Universitario” from Valladolid as part of the routine diagnostic 
procedures. Informed consent was obtained from patients, and the study 
protocol was approved by the Ethics Committee from both “Hospital Clínico 
Universitario” and Faculty of Medicine, University of Valladolid. 
 
Biopsy Culture 
Three intestinal biopsy explants were collected from each individual and 
cultured in vitro as previously described (25). Briefly, all biopsies were collected 
in ice-chilled PBS (Cambrex Iberia Products, Barcelona, Spain) containing 0.1% 
Gentamicine (Cambrex) and cultured within 1 hour in RPMI 1640 (Cambrex) 
supplemented with 10% heat-inactivated FBS (Cambrex), penicillin (100 U/mL), 
streptomycin (100 μg/ml) (Cambrex) and fungizone (0.25 μg/ml) (Cambrex). 
Each sample cultured in basal medium constituted an internal control. One 
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explant from each patient was in vitro challenged with a gliadin solution (100 
μg/ml) (Sigma, St Louis, MO, USA) for only three hours, what is considered 
normal timing and concentration in the duodenum after a meal, while a second 
explant was co-cultured both with gliadin (100 μg/ml) and 20mM of ascorbate 
(Sigma, St Louis, MO, USA), a potent non-toxic NF-κB inhibitor (24). All 
reagents were checked and discarded for lypopolisaccharide (LPS) 
contamination with Lymulus amebocyte lisate, PYROGENT ® Plus (Cambrex) 
(Detection limit 0.06 EU/ml). Tissue culture was carried out by immersion in 
culture dishes placed in a cell incubator with 5% CO2 at 37ºC. After three hours, 
biopsy specimens were washed up in PBS containing 0.1% Gentamicine 
(Cambrex) and later cultured for another 21 hours in new clean culture medium 
to determine whether gliadin challenge is followed by a secondary response. 
After 24 hours (3 hours with stimulus + 21 hours with basal medium), tissue was 
embedded in RNAlater (Ambion) and snap-frozen until protein isolation 
extraction using the TRIZOL® reagent according to the protocol provided by the 
manufacturer. Supernantants were collected both at 3 and 24 hours. 
 
Effector molecules on culture supernantants. 
Biopsy culture supernatants after 3 hours of culture were assayed for the 
indirect evaluation of nitric oxide by applying the Griess Reaction which 
measures the total amount of nitrites, a primary metabolite derived from the 
instantaneous oxidation of nitric oxide (Molecular Probes, detection limit (D.L.) 
1μM) following manufacturer´s instructions. Supernatants at 24 hours were also 
analyzed by using a multiplex assay (Biorad, Hercules, CA) on a Luminex TM 
platform (Austin, TX), following manufacturer´s instructions, for the 
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concentration of interferon γ (IFN-γ) [D.L. 3.38 pg/ml], tumour necrosis factor α 
(TNF-α) [D.L. 4.331pg/ml], IFN- [D.L. 89.87 pg/ml], interleukin (IL)-17 [12.98 
pg/ml], IL-13 [D.L. 3.49 pg/ml] and IL-6 [0.19 pg/ml]. 
 
Western blot analysis 
8µg of protein isolated from whole biopsy explants were added per well. They 
were separated by using a 15% acrilamide/bisacrilamide (37.5:1) gel in a mini-
Protean II (BioRad Laboratories Inc, USA), and later transferred onto PVDF 
membranes of 0,45 Micron (Pierce Biotechnology Inc. IL, USA). Membranes 
were incubated with primary specific antibodies to human IL-15 (mouse 
monoclonal MAB247, R&D) at a final dilution of 1/400, performing a second 
incubation with antibodies to mouse IgG labelled with horseradish peroxidase 
(Amersham Biosciences Europe, Freiburg, Germany). Chemiluminiscent 
substrate Lumigen PS-3 (Amersham) and autoradiography film Hyperfilm ECL 
(Amersham) were used for developing. Recombinant human IL-15 (Peprotech, 
London, UK) was used as a positive control. 
 
STATISTICAL ANALYSIS 
The Friedman test was applied in all cases to compare different culture 
conditions from the same patient (nonparametric and paired two-tailed test). 
The secondary Wilcoxon matched paired test between pairs of conditions was 
only applied in those cases where the Friedman test was statistically significant. 
The level of significance was fixed at p <0.05. 
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RESULTS 
Ascorbate blocks the increased nitrites secretion induced by gliadin 
challenge in biopsy samples from CD patients  
Statistically significant differences were found in nitrite secretion after three 
hours of culture when explants from the same patient were compared in basal 
conditions and after gliadin-challenge, both with and without ascorbate 
supplementation (p<0.001). Gliadin challenged increased the secretion of 
nitrites, therefore indicating an increase in the secretion of Nitric Oxide, in 
duodenal explants from treated CD patients (Figure 1) (p<0.05) compared to 
non-challenged explants from the same patient as previously described (26, 
27). The addition of ascorbate to gliadin-challenge cultures effectively blocked 
the induction of nitrite secretion by gliadin at a non-toxic concentration of 20mM 
(p< 0.05, Figure 1). Because ascorbate is also a strong antioxidant, and given 
that the Griess reaction is based on the determination of nitrites (mainly derived 
from the oxidation of nitric oxide), these results could reflect an experimental 
artifact. Therefore, to confirm whether ascorbate really blocks the immune 
response to gliadin, we have also studied the secretion of cytokines on culture 
supernantants. 
 
Ascorbate inhibits cytokine secretion induced by gliadin challenge in 
biopsy samples from CD patients 
When studying cytokine secretion at 24 hours (3 hours of gliadin challenge plus 
21 hours of basal culture), the Friedman test was statistically significant for IFN 
(p<0.05), TNF (p<0.01), IFN (p<0.05) and IL-6 (p<0.01) (Figure 2). After 
gliadin challenge, none of the assayed cytokines was statistically increased 
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compared to the basal culture. However, the addition of ascorbate to culture 
medium clearly decreased the secretion of all the cytokines, compared to non-
ascorbate supplemented gliadin-challenged supernatants (Figure 2). The 
decrease was statistically significant for IFN (p<0.05), TNF (p<0.05), IFN 
(p<0.05) and IL-6 (p<0.05). Moreover, in these cases cytokine secretion was 
downregulated even to lower values than those observed in basal cultures 
(IFN: p<0.05; TNF: p<0.05; IFN: p<0.05; and IL-6: p<0.01) (Figure 2), 
therefore confirming its inhibitory properties.  
 
Ascorbate inhibits duodenal IL-15 
Basal IL-15 production in biopsy explants was only detectable in one out of 8 
treated-CD patients and was absent in all 3 non-CD controls (Figure3). After 
gliadin-challenge, as previously described (6, 28, 29), gliadin induced IL-15 
production in treated-CD patients, since it was detected in 7 out of 8 cases 
(Figure 3). Similar results were obtained in non-CD controls, where gliadin was 
also revealed as an IL-15 inducer in all 3 non-CD cases compared to basal 
culture, as previously reported by our group (29). Interestingly, gliadin-induced 
IL-15 had detectable levels even 21 hours after gliadin was removed from 
culture medium, given that Western blot was performed at the end of the culture 
(3 hours of gliadin challenge and 21 hours in basal condition). As expected, the 
addition of ascorbate to culture medium completely inhibited IL-15 production 
not only in CD biopsy explants but also in those from non-CD controls. 
Moreover, it is noteworthy that the IL-15 inhibition by ascorbate took place even 
in the only treated CD-patient who had basal IL-15 production. 
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DISCUSSION  
In this paper we have demonstrated by using a culture model of duodenal 
explants that the addition of ascorbate to culture medium blocks the immune 
response to gluten. Moreover, we have blocked the induction of nitrites (and 
probably reflecting an blocking of the iNOS pathway) and down-regulated the 
secretion of proimflammatory cytokines (IFN, TNF, IFN and IL-6) but we 
have also completely inhibited IL-15 production. Moreover, the IL-15 inhibition 
took place even a CD patient who had had IL-15 expression in the basal 
culture. 
Although it has been largely reported that gliadin is a potent cytokine inducer in 
CD patients by using culture models -what is specially true in the cases of IFN 
and TNF (4, 26)-, there was no statistically significant up-regulation of any of 
the assayed cytokines in our cultures (Figure 2). The explanation to this 
discrepancy probably resides in the experimental design, since our gliadin-
challenges were only performed for 3 hours (considered to be the normal transit 
time of dietary antigens through the duodenum) followed by 21 extra hours in 
basal conditions. Thus, since the challenging time is lower that previous studies 
in which challenge was performed for 24 hours, it is reasonably to think that the 
total amount of cytokine released would be smaller than those studies, and 
therefore the cytokine increase would not be statistically significant.  
In this study paper we have confirmed that a non toxic (20mM) supplementation 
of ascorbate to gliadin challenges inhibited the gliadin-induced nitrite 
production, probably derived from iNOS induction (30, 31), as well as secretion 
of IFN, TNF, IFN and IL-6. In addition, these four cytokines decreased its 
expression to lower values than those observed in basal cultures (Figure 2). 
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Moreover, ascorbate also blocked IL-15 induction, considered to be a central 
cytokine in CD immunopathogenesis given its unique properties of both 
initiating the innate immune response to gliadin (6, 28) as well as activating 
dendritic cells (15, 16, 32) and facilitating the development of the secondary 
adaptive response (3). Future studies addressing whether ascorbate is also 
capable of inhibiting DCs maturation in the CD duodenum and even its capacity 
to generate regulatory T cells (33) to gliadin should be carried out. 
It has been recently shown that oral supplementation of ascorbate attenuated 
anaphylactic reaction to soybean glycinin-induced hipersensensitivity on a 
swine model (34). In humans, oral supplementation has been reported to delay 
the progression of transplant-associated coronary arteriosclerosis (35), the 
progression of cardiac transplant-associated arteriosclerosis (36), and even 
reduced xenobiotic-induced T-cell hyperactivation (37). Ascorbate is also 
capable of inhibit phytohaemagglutinin and concanavalin A mitogen-stimulated 
peripheral blood mononuclear cells by suppressing both formation and release 
of IFN (38). Ascorbate is also capable of inhibiting DC activation as well as its 
TH1 cytokine secretion and immunostimulatory capacity. Moreover, ascorbate-
treated DCs were also able to generate regulatory T cells with FoxP3+ 
expression (33). All together, these results clearly point out the possible 
therapeutical use of ascorbate in diseases, like CD. However, further studies 
are needed before this approach would be feasible, including for instance the 
characterization of the optimal amount of ascorbate to be provided to the 
patients..  
As a final remark, ascorbate is revealed as a possible future alternative therapy 
to the GFD. This effect should be deeper studied given the relevance of our 
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findings. Futures studies should confirm these results, and specifically should 
study the coeliac DCs immunomodulation by ascorbate, given that they are 
central players in the CD immune response. These obtained results would 
provide new insights in the possibility of a new cheap and safe alternative 
and/or complementary treatment in CD. 
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FIGURE 1 
Organ culture secretion of nitrites in 8 treated CD patients after 3 hours of 
gliadin challenge (100μg/ml) with (Gli+Ascorb) and without (Gli) ascorbate 
supplementation (20mM), compared to basal culture (all at the 3 hours). 
Statistically significant differences are shown (p<0.05, Wilcoxon matched paired 
test). Horizontal bars indicate median and whiskers maximum and minimum 
values. IQR: interquartile range. 
 
FIGURE 2 
Organ culture secretion of IFN-γ, TNF-α, IFN-, IL-17, IL-13 and IL-6 in 8 
treated CD patients after gliadin challenge (100μg/ml) with (Gli+Ascorb) and 
without (Gli) ascorbate supplementation (20mM) (3 hours of challenge and 21 
hours of basal culture) compared to the basal culture. Statistically significant 
differences are shown (p<0.05, Wilcoxon matched paired test). Horizontal bars 
indicate median and whiskers maximum and minimum values. IQR: interquartile 
range. 
 
FIGURE 3 
Representative western-blot analysis using whole protein biopsy explants after 
24 hours of basal culture (lanes 1, 4), and after 3 hours of gliadin challenge 
(100μg/ml) with (lanes 3, 6) and without (lanes 2, 5) ascorbate (20mM) 
supplementation and 21 hours of basal culture. C: human recombinant IL-15 
lane.  
Basal IL-15 was only detected in one CD patient. Gliadin induced IL-15 
production both in non-CD controls (3 out of 3) and treated CD patients (7 out of 
8). Ascorbate inhibited IL-15 production in all the cases, even in one patient 
who had basal detectable levels of IL-15. 
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ABSTRACT 
BACKGROUND: the IL-15/NF-κB axis has an important role in Coeliac Disease 
(CD) and may represent a molecular target for its immunomodulation. 
Ascorbate (Vitamin C) is known to show inhibitory effects on NF-κB.   Therefore, 
we studied if ascorbate supplementation to gliadin challenges could down-
regulate the mucosal immune response to gliadin in CD. 
METHODS: Duodenal biopsy explants from treated CD patients were gliadin 
challenged in vitro (100 μg/ml) with and without 20mM ascorbate. An extra 
tissue explant in basal culture was used as internal control. Secretion levels of 
nitrites (3 hours), and IFN-γ, TNF-α, IFN-α, IL-17, IL-13 and IL-6 (24 hours) 
were measured on the supernatants. IL-15 was assayed by Western-blot on 
whole protein duodenal explants. 
RESULTS: The addition of ascorbate to in vitro culture gliadin-challenged 
biopsies blocked the secretion of nitrites (p=0.013), IFNγ (p=0.0207), TNFα 
(p=0.0099), IFNα (p=0.0375) and IL-6 (p=0.0036) compared to samples from 
non-ascorbate supplemented culture. Cytokine secretion was downregulated by 
ascorbate even to lower values than those observed in basal cultures (IFNγ: 
p=0.0312; TNFα: p=0.0312; IFNα: p=0.0312; and IL-6: p=0.0078). Gliadin-
challenge induced IL-15 production in biopsies from treated CD patients while 
the addition of ascorbate to culture medium completely inhibited IL-15 
production. Moreover, the inhibition of IL-15 by ascorbate took place even in the 
only treated CD-patient who had basal IL-15 production. 
CONCLUSIONS: Ascorbate decrease the mucosal inflammatory response to 
gluten in an intestinal biopsy culture model, so it might be revealed as a 
possible future supplementary therapy in CD. 
*'Revised & Marked' Manuscript
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INTRODUCTION 
Coeliac Disease (CD) is a common gastro-intestinal disorder caused by an 
hypersensitivity reaction to wheat gliadin and similar proteins from rye and 
barley, affecting genetically predisposed individuals (HLA-DQ2/DQ8). The 
current treatment is a life-long strict gluten-free diet (GFD) (1 ,2).  
The most accepted model of the CD immunopathogenesis is the two-signal 
model, which establishes that gliadin has a dual effect on the CD duodenum, 
triggering the development of an innate immune response in the epithelium, and 
activating an adaptive immune response controlled by gluten-reactive T cells 
with a Th1 cytokine profile (3, 4). Innate immunity, and specifically interleukin 
(IL)-15 (5, 6), plays a key role in the development of CD through a DQ2-
independent mechanism (7). The induction of IL-15 seems to be involved in the 
initial stages of the disease leading to epithelial stress, increase tight-junction 
permeability, enterocyte apoptosis and dendritic cell (DC) activation (5, 6, 8, 9, 
10, 11, 12), facilitating the development of the secondary adaptive response (3). 
Moreover, the gliadin amplifies the production of inflammatory cytokines through 
the Nuclear Factor (NF)-κB (13) with a positive feedback by IL-15, which is also 
a potent NF-κB activator (14). Moreover, DCs are important players in the 
connection between the innate and the subsequent adaptive immune response 
(15), and require NF-κB for its development, survival, function and cytokine 
production (16, 17, 18). Thus, the IL-15/NF-κB axis is revealed to have an 
important role in the pathogenesis of CD and may represent a molecular target 
for strategies of immunomodulation (19).  
NF-κB is a heterogeneous collection of dimeric proteins subjected to a complex 
regulatory mechanism (20, 21), involving the inhibitory proteins I-κB that bind to 
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NF-κB subunits which became active after dissociation. This takes place when 
NF-κB inducers promote I-κB phosphorylation mediated by two I-κB kinases 
(IKKs), and targets I-κB for its degradation by the 26S proteaseome (22, 23), 
followed by translocation of NF-κB dimmers to the nucleus and elicit their 
function. It has been recently proposed that ascorbate, may be able to inhibit 
IKK activation and, therefore, by blocking I-κB phosphorylation, NF-κB cannot 
translocate and bind to its DNA targets (24). These inhibitory properties of 
ascorbate can be elicited at concentrations of 20mM, intracellularly in vivo, 
without showing toxic effects to cells, or inhibiting other inducible factors.  
The nitric oxid (NO) is involved in the histological changes produced in coeliac 
disease. In the mouse monocyte/macrophage cell line RAW 264.7, pre-
challenged with IFNγ, the gliadin is able to enhance the NF-κB activity and 
iNOS protein expression and therefore NO production. Both effects were 
reduced by NF-κB activation inhibitors, thereby indicating that gliadin should 
modulate iNOS gen expression through NFKB activation (25). 
Given the role of the NF-κB pathway in the pathogenesis of CD, we wondered 
whether ascorbate has an effect on the inhibition of the early/innate immune 
response triggered by gluten and, therefore, can be used as a supplementary 
therapeutical strategy to GFD on CD patients. To address this question we have 
cultured biopsies from treated CD patients stimulated in vitro with gliadin, with 
and whithout supplementation of ascorbate. Our data confirm that ascorbate 
inhibits the gliadin-induced expression of IL-15 in CD biopsy explants. 
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MATERIALS AND METHODS 
Study Subjects 
We studied 8 CD patients treated on a GFD for a minimum of 6 months (mean 
age 41.7 years, range 23-68 yr, 25.0% males) and 3 non-CD healthy controls 
(mean age 63.6 yr, range 61-68, 0.0% males). The diagnosis of CD was based 
on compatible symptoms, positive serology (IgA antiendomysial or 
antitransglutaminase antibodies), positive genetic markers (HLA-DQ2/8), and 
mucosal changes in the duodenum. At the time of sample collection, CD 
patients had mucosal recovery (Marsh 0-1) and negative serology for at least 
one year. Healthy controls were referred to the Gastroenterology Clinics due to 
other intestinal diseases which were later ruled out, and no mucosal alterations 
were found in the duodenum. All patients were attended to the Adult 
Gastroenterology Clinics from the “Hospital Clínico Universitario”, Valladolid, as 
part of the routine diagnostic procedures. Informed consent was obtained from 
patients, and the study protocol was approved by the Ethics Committee from 
both “Hospital Clínico Universitario” and Faculty of Medicine, University of 
Valladolid. 
 
Biopsy Culture 
Three intestinal biopsy explants were collected from each individual and 
cultured in vitro as previously described (26). Briefly, all biopsies were collected 
in ice-chilled PBS containing 0.1% Gentamicine and cultured within 1 hour in 
RPMI 1640 supplemented with 10% heat-inactivated FBS, Penicillin (100 U/ml), 
Streptomycin (100 μg/ml) and Fungizone (0.25 μg/ml) (all from Cambrex Iberia 
Products, Barcelona, Spain). One sample from each individual was cultured in 
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basal medium was used as an internal control. One explant from each patient 
was challenged in vitro with a gliadin solution (100 μg/ml) (Sigma, St Louis, MO, 
USA) for only three hours, which is considered normal exposure and 
concentration in the duodenum after a meal. A second explant was co-cultured 
both with gliadin (100 μg/ml) and 20mM of ascorbate (Sigma), a potent non-
toxic NF-κB inhibitor (24). After three hours, biopsy explants specimens were 
washed up in PBS containing 0.1% Gentamicine and later cultured for another 
21 hours in new clean culture medium to determine whether gliadin challenge is 
followed by a secondary response. Tissue culture was carried out in vitro by 
immersion in culture dishes placed in a cell incubator with 5% CO2 at 37ºC. 
After 24 hours (3 hours with stimulus + 21 hours with basal medium), tissue was 
embedded in RNAlater (Ambion, Applied Bisystems, Austin, TX, USA) and 
snap-frozen until protein extraction using the TRIZOL® Reagent (Invitrogen, 
Carlsbad, CA, USA) according to the manufacturer´s protocol. Supernatants 
were collected both at 3 and 24 hours. All reagents were checked and 
discarded for lypopolisaccharide (LPS) contamination with Lymulus amebocyte 
lisate, PYROGENT ® Plus (Cambrex) (Detection limit 0.06 EU/ml). 
 
Effector molecules on culture supernantants. 
Biopsy culture supernatants after 3 hours of culture were assayed for the 
concentration of oxidative stress by applying the Griess Reaction following 
manufacturer´s instructions (Molecular Probes, Invitrogen) (detection limit (D.L.) 
1μM). The nitric oxid (NO) is very unstable therefore the Griess Reaction 
measures the total amount of nitrites, which are primary metabolites derived 
from the instantaneous oxidation of nitric oxide. Supernatants at 24 hours of 
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culture were also analyzed by using a multiplex assay on a Luminex TM 
platform (BioRad, Hercules, CA, USA), for the concentration of IFNγ [D.L. 3.38 
pg/ml], tumour necrosis factor α (TNFα) [D.L= 4.331pg/ml], IFNα [D.L= 89.87 
pg/ml], IL-17 [D.L= 12.98 pg/ml], IL-13 [D.L= 3.49 pg/ml] and IL-6 [D.= 0.19 
pg/ml]. 
 
Western blot analysis 
From whole biopsy explants, 8µg of protein isolated were added per well. They 
were separated by using a 15% acrilamide/bisacrilamide (37.5:1) gel in a mini-
Protean II (BioRad), and later transferred onto PVDF membranes of 0.45 
Micron (Pierce Biotechnology Inc. IL, USA). Membranes were incubated with 
primary specific antibodies to human IL-15 (mouse monoclonal MAB247) (R&D, 
Minneapolis, MN, USA) at a final dilution of 1/400, performing a second 
incubation with antibodies to mouse IgG labelled with horseradish peroxidase 
(Amersham Biosciences Europe, Freiburg, Germany). Chemiluminiscent 
substrate Lumigen PS-3 (Amersham) and autoradiography film Hyperfilm ECL 
(Amersham) were used for developing. Recombinant human IL-15 (Peprotech, 
London, UK) was used as a positive control. 
 
Statistical analysis 
The Friedman test was applied in all cases to compare different culture 
conditions from the same patient (nonparametric and paired two-tailed test). 
The secondary Wilcoxon matched paired test between pairs of conditions was 
only applied in those cases where the Friedman test was statistically significant. 
The level of significance was fixed at p <0.05. 
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RESULTS 
Ascorbate blocks the secretion of nitrites induced by gliadin challenge in 
biopsy samples from CD patients  
Statistically significant differences were found in nitrites secretion after three 
hours of culture when explants from the same patient were compared in basal 
conditions and after gliadin-challenge, both with and without ascorbate 
supplementation (p<0.001). Gliadin challenge increased the secretion of nitrites, 
therefore indicating an increase in the production of nitric oxide (NO) in 
duodenal explants from treated CD patients (p<0.05) (Figure 1) compared to 
non-challenged explants from the same patient as previously described (27, 
28). The addition of ascorbate, at a non-toxic concentration of 20mM, to gliadin-
challenged cultures effectively blocked the induction of nitrite secretion by 
gliadin (p< 0.05) (Figure 1). Because ascorbate is also a strong antioxidant, and 
given that the Griess reaction is based on the determination of nitrites (mainly 
derived from the oxidation of NO), these results could reflect an experimental 
artifact. To confirm that ascorbate really blocks the immune response to gliadin, 
we have also studied the secretion of cytokines on culture supernantants.  
 
Ascorbate inhibited the secretion of cytokines induced by gliadin 
challenge in biopsy samples from CD patients 
Our findings showed that in the supernatants at 24 hours (3 hours of challenge 
with gliadin plus 21 hours of basal culture) none of the assayed cytokines were 
statistically increased compared to the basal culture. However, the addition of 
ascorbate to culture medium, for those 3 hours of challenge, clearly decreased 
the secretion of all cytokines, compared to non-ascorbate supplemented gliadin-
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challenged supernatants (Figure 2). The decrease was statistically significant 
for IFNγ (p=0.0156), TNFα (p=0.0312), IFNα (p=0.0469) and IL-6 (p=0.0312). 
Moreover, in these cases cytokine secretion was downregulated even to lower 
values than those observed in basal cultures (IFNγ: p=0.0312; TNFα: p=0.0312; 
IFNα: p=0.0312; and IL-6: p=0.0078) (Figure 2), thereby confirming its inhibitory 
properties.  
 
Ascorbate inhibited duodenal IL-15 
Basal IL-15 production in biopsy explants was only detectable in one out of 8 
treated-CD patients and was absent in all 3 non-CD controls (Figure3). After 
gliadin-challenge, as previously described (6, 29, 30), gliadin induced IL-15 
production in treated-CD patients. In this assay it was detected in 7 out of 8 
cases (Figure 3). Similar results were obtained in non-CD controls, where 
gliadin was also revealed as an IL-15 inducer in all 3 non-CD cases compared 
to basal culture, as previously reported by our group (30). Gliadin-induced IL-15 
had detectable levels even 21 hours after gliadin was removed from culture 
medium, given that Western blot was performed at the end of the culture (3 
hours of gliadin challenge and 21 hours in basal condition). As expected, the 
addition of ascorbate to culture medium completely inhibited IL-15 production 
not only by CD biopsy explants but also by those from non-CD controls. 
Moreover, it is noteworthy that the IL-15 inhibition by ascorbate took place even 
in the only treated CD-patient who had basal IL-15 production. 
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DISCUSSION  
In this study we have shown, by using a culture model of duodenal explants, 
that the addition of ascorbate to culture medium decrease the secretion of 
inflammatory mediators in response to gluten in CD patients. Supplementation 
of ascorbate, of a non toxic concentration of 20mM, to gliadin challenged biopsy 
culture not only inhibits the gliadin-induced production of nitrites, but also down-
regulates the secretion of proinflammatory cytokines (IFN, TNF, IFN and IL-
6), and completely inhibits the of IL15.  
Although it has been largely reported that gliadin is a potent cytokine inducer in 
CD patients by using culture models - especially in the cases of IFN and TNF 
(4, 27), no statistically significant up-regulation of cytokine expression was 
observed in any of the culture supernatants (Figure 2). The explanation to this 
discrepancy probably resides in the experimental design, where the time of 
challenge in culture (3 hours, which is considered a normal exposure and 
concentration in the duodenum after a meal, followed by 21 extra hours in basal 
conditions) was lower than previous studies in which challenge was performed 
for 24 hours. In this situation, is reasonable to think that the total level of 
cytokine released should be smaller than previous studies.  
Gliadin is capable of increasing the production of NO and this is related to the 
expression of iNOS. In addition, gliadin increased the binding activity of NF-
κB/DNA, the degradation of IκBα and the nuclear translocation of p50 and p65 
subunits (25). 
With these findings we have confirmed that by using a non toxic (20mM) 
supplementation of ascorbate to biopsy culture challenged with gliadin, the 
gliadin-induced production of nitrites is inhibited. The effects of gliadin are 
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probably mediated by iNOS and ascorbate acts blocking its pathway (25, 31). 
The expression levels of the cytokines IFN, TNF, IFN and IL-6 are 
decreased below to those levels observed in basal cultures (Figure 2). This 
decrease could be the result of the inhibition of the NF-κB pathway induced by 
ascorbate.  
Moreover, ascorbate also affects the IL-15 pathway. This property of ascorbate 
is very interesting because IL15 is considered to be a central cytokine in CD 
immunopathogenesis given its capacity to initiate the innate immune response 
to gliadin (6, 29) and to activate dendritic cells (15, 16, 32), therefore facilitating 
the development of the secondary adaptive response (3).  
Ascorbate is capable of inhibiting DC activation, blocking cytokine secretion and 
the immunostimulatory properties. Moreover, ascorbate-treated DCs are able to 
generate regulatory T cells with FoxP3+ expression (33). Future studies should 
address whether ascorbate is also capable of inhibiting DCs maturation in the 
duodenum of CD patients and even its capacity to generate gliadin specific 
regulatory T cells (33). 
It has been recently shown that oral supplementation of ascorbate attenuate 
several anaphylactic reactions to soybean glycinin-induced hipersensensitivity 
on a swine model (34). In humans, oral supplementation has been reported to 
delay the progression of transplant-associated coronary arteriosclerosis (35), 
and of cardiac transplant-associated arteriosclerosis (36), and even reduces 
xenobiotic-induced T-cell hyperactivation (37). Ascorbate is also capable of 
inhibit phytohaemagglutinin and concanavalin A mitogen-stimulated peripheral 
blood mononuclear cells by suppressing both formation and release of IFN 
(38). All together, these results clearly point out to the possible therapeutical 
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use of ascorbate in diseases, like CD. However, further studies are needed to 
confirm this, including double-blind placebo-controlled trails aiming to 
characterize not only the optimal dosis in vivo of ascorbate, but also the safety 
amount of gluten intake tolerated by patients on an ascorbate trial. 
As a final remark, this property of ascorbate of modulating the immunologic 
response to gluten could be used as a suplement to the GFD. Considering the 
residual amount of gluten that some “free gluten products” still have, ascorbate 
could be a necessary supplement to the dietary treatment of CD. Given the 
relevance of our findings, this effect should further studied in order to confirm 
these results, and specifically to analyze how ascorbate exerts its 
immunomodulatory effects on DCs, given that they are central players in the CD 
immune response.  
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FIGURE 1 
Biopsy culture secretion of nitrites in 8 treated CD patients after 3 hours of 
gliadin challenge (100μg/ml) with (Gli+Ascorb) and without (Gli) ascorbate 
supplementation (20mM), compared to basal culture (all at the 3 hours). 
Statistically significant differences are shown (p<0.05, Wilcoxon matched paired 
test). Horizontal bars indicate median and whiskers maximum and minimum 
values. IQR: interquartile range. 
 
FIGURE 2 
Supernatants Biopsy culture secretion of IFN-γ, TNF-α, IFN-, IL-17, IL-13 and 
IL-6 in 8 treated CD patients after gliadin challenge (100μg/ml) with 
(Gli+Ascorb) and without (Gli) ascorbate supplementation (20mM) (3 hours of 
challenge and 21 hours of basal culture) compared to the basal culture. 
Statistically significant differences are shown (p<0.05, Wilcoxon matched paired 
test). Horizontal bars indicate median and whiskers maximum and minimum 
values. IQR: interquartile range. 
 
FIGURE 3 
Representative western-blot analysis using whole protein biopsy explants of 
non-CD controls and treated-CD patients, after 24 hours of basal culture 
(Basal), and after 3 hours of gliadin challenge (100μg/ml) with (Gli+Asc) and 
without (Gli) ascorbate supplementation (20mM) and 21 hours of basal culture. 
C: human recombinant IL-15 lane.  
Basal IL-15 was only detected in one CD patient. Gliadin induced IL-15 
production both in non-CD controls (3 out of 3) and treated CD patients (7 out of 
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8). Ascorbate inhibited IL-15 production in all cases, even in a patient who had 
detectable basal levels of IL-15. 
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